Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10875)
  2. Meeting Abstract (9464)
  3. Review (551)
  4. Book Section (417)
  5. Editorial (334)
  6. Guidelines (157)
  7. Correspondence (116)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22139)
  2. GSK Faculty (5904)
  3. Genitourinary Oncology Service (5632)
  4. Survivorship Research (5206)
  5. Gastrointestinal Oncology Service (4671)
  6. Breast Medicine Service (4121)

More Groups

People
  1. Robert Motzer (1246)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (870)
  6. Leonard Saltz (791)

More People

Years
  1. 2025 (540)
  2. 2024 (1386)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5253)
  2. Annals of Oncology (1295)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (772)
  5. Journal of Thoracic Oncology (531)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5544)
  2. Elsevier Inc. (2654)
  3. American Association for Cancer Research (2322)
  4. Oxford University Press (1812)
  5. Nature Publishing Group (1030)
  6. Springer (979)

More Publishers

Results (22161)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Definitive chemoradiation with proton therapy for nasal cavity malignancies for organ preservation or unresectable disease
    Meeting Abstract

    Yang, F.; Mankuzhy, N.; Sherman, E.; Cohen, M.; Lee, N.
    Radiotherapy and Oncology (2024)

    Fulltext@MSK | Save
  • Electronic symptom monitoring during metastatic cancer treatment: Does it work better for some patients than for others (AFT-39)?
    Meeting Abstract

    Deal, A.; Ginos, B.; Schrag, D.; Jansen, J.; Henson, S.; Stover, A.; Carr, P.; Spears, P.; Jonsson, M.; Bennett, A.; more...
    Quality of Life Research (2024)

    Fulltext@MSK | Save
  • Association between alert notification intensity during early study participation and time to study discontinuation in the AFT-39 PRO-TECT cluster-randomized clinical trial
    Meeting Abstract

    Ginos, B.; Dueck, A. C.; Schrag, D.; Jansen, J.; Henson, S.; Stover, A. M.; Carr, P.; Spears, P. A.; Jonsson, M.; Deal, A. M.; more...
    Quality of Life Research (2024)

    Fulltext@MSK | Save
  • Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis
    Meeting Abstract

    Kümmel, S.; Jhaveri, K.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Randomized phase 3 study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaive, RET-mutant medullary thyroid cancer
    Meeting Abstract

    Hadoux, J.; Elisei, R.; Brose, M.; Hoff, A.; Robinson, B.; Gao, M.; Jarzab, B.; Isaev, P.; Kopeckova, K.; Wadsley, J.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Möhler, M.; Janjigian, Y.; Al-Batran, S. E.; Wainberg, Z.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L.; Oh, D. Y.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Meeting Abstract

    Loong, H.; Goto, K.; Solomon, B.; Park, K.; Pérol, M.; Arriola, E.; Novello, S.; Cheng, Y.; Ardizzoni, A.; Mak, M.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Meeting Abstract

    Heinemann, V.; André, T.; Bekaii-Saab, T.; Cercek, A.; Nakamura, Y.; Raghav, K.; Siena, S.; Strickler, J.; Van Cutsem, E.; Adelberg, D.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
    Meeting Abstract

    Möhler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, S. L.; Kudo, M.; Sangro, B.; Kelley, K.; Furuse, J.; Park, J. W.; Sunpaweravong, P.; Fasolo, A.; Yau, T.; Kawaoka, T.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save